Continued ATM sales and warrant exercises will further dilute existing shareholders. Monitor cash runway and next quarterly update for guidance on capital needs. The massive authorized capital (DKK 100M) gives the board flexibility for further dilutive raises.
How the stock moved after the report
BEARISH VIEWSTOCK ABOVE ENTRY AT T+20- T+0 · Sep 4 $3.12entry
- T+1 · 2mo ago +1.60%α +2.15% · $3.17
- T+5 · 2mo ago −1.60%α −0.39% · $3.07
- T+20 · 6w ago +0.96%α +0.36% · $3.15
- T+50 · todayOpen
- T+60 · in 14d Pending
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Evaxion A/S raised $2.1M net through an at-the-market (ATM) offering of 681,268 ADSs at an average price of $3.1987 per ADS between August 19-21, 2026. The company concurrently registered share capital increases totaling nominal DKK 8,515,850, bringing total share capital to DKK 112,768,539. The accompanying Articles of Association reveal massive warrant overhang and broad authorization for further dilutive issuances, underscoring ongoing cash burn and shareholder dilution for this pre-revenue biotech.
Key Facts
- Sold 681,268 ADSs in ATM offering at avg $3.1987/ADS, net proceeds $2,113,767
- Share capital increased to nominal DKK 112,768,539 (451,074,156 shares of DKK 0.25 each)
- Board authorized to issue up to nominal DKK 100M in shares without pre-emptive rights (section 3.1)
- Outstanding warrants include 99.9M+ warrants to investors/lenders with exercise prices far above current market price
- 29,925,000 prefunded warrants exercised by Jan 2025; 52.8M warrants exercised by Nov 2025
Financial Impact
ATM raised $2.1M net, representing ~8% of $26M market cap; ongoing dilution from warrant exercises and authorized capital
Risk Factors
- Ongoing dilution from ATM program and outstanding warrants
- Pre-revenue status with no approved products or revenue stream
- Cash burn requires frequent capital raises, pressuring stock price
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 4 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 6-K Filing (EVAX), Batch item 1 | 0001171843-26-005887 |
| Document: f6k_090426.htm | 0001171843-26-005887 |
| Document: 0001171843-26-005887-index-headers.html | 0001171843-26-005887 |
| Document: 0001171843-26-005887.txt | 0001171843-26-005887 |
Track record
50 reports on EVAX
7 of 10 bullish or bearish reports moved the stock their way by T+1. Best: +22.94% at T+5 after the Mar 5, 2026 report. 9 of 10 went positive at some point.
Filters
- Nov 12, 20264d ago 6-K Neutral 2/10 Entry $2.77 to $2.74 Now $2.77 −0.00% ▼ −1.08% −0.72% vs SPY
- Nov 12, 20264d ago Press Release Neutral 1/10 Entry $2.77 to $2.74 Now $2.77 −0.00% ▼ −1.08% −0.72% vs SPY
- Nov 9, 20267d ago 6-K / F-1/A / PRESS-RELEASE Neutral 3/10 Entry $2.75 to $2.86 Now $2.77 +0.73% ▲ +4.00% +4.37% vs SPY
- Nov 6, 202610d ago 6-K Neutral 4/10 Entry $3.00 to $2.75 Now $2.77 −7.67% ▼ −8.33% −10.70% vs SPY
- Nov 6, 202610d ago Press Release Neutral 4/10 Entry $3.00 to $2.75 Now $2.77 −7.67% ▼ −8.33% −10.70% vs SPY
- Nov 4, 202612d ago 6-K Neutral 3/10 Entry $2.97 to $2.76 Now $2.77 −6.73% ▼ −7.07% −2.66% vs SPY
- Nov 4, 202612d ago 6-K Neutral 3/10 Entry $2.97 to $2.76 Now $2.77 −6.73% ▼ −7.07% −2.66% vs SPY
- Nov 3, 202613d ago 6-K Neutral 4/10 Entry $2.96 to $2.97 Now $2.77 −6.42% ▲ +0.34% −1.31% vs SPY
- Oct 30, 202617d ago 6-K Neutral 2/10 Entry $2.93 to $2.92 Now $2.77 −5.46% ▼ −0.34% +0.14% vs SPY
- Oct 30, 202617d ago Press Release Neutral 3/10 Entry $2.93 to $2.92 Now $2.77 −5.46% ▼ −0.34% +0.14% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers